Evidence map›Paper›PMID 32843912›Full record

ReviewWorld journal of stem cells2020

Potential of transposon-mediated cellular reprogramming towards cell-based therapies.

Dharmendra Kumar, Taruna Anand, Thirumala R Talluri, Wilfried A Kues

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of stem cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Bovine Pluripotent Stem Cells: Current Status and Prospects.International journal of molecular sciences · 2024
    Review
  2. Review
  3. Review
  4. Article
  5. piggyBac system to co-express NKG2D CAR and IL-15 to augment theMolecular therapy. Methods & clinical development · 2021
    Article
  6. Review
  7. Perspectives of pluripotent stem cells in livestock.World journal of stem cells · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Dharmendra KumarAnimal Physiology and Reproduction Division, ICAR-Central Institute for Research on Buffaloes, Hisar 125001, India. dharmendra.kumar@icar.gov.in.
Taruna AnandNCVTC, ICAR-National Research Centre on Equines, Hisar 125001, India.
Thirumala R TalluriEquine Production Campus, ICAR-National Research Centre on Equines, Bikaner 334001, India.
Wilfried A KuesFriedrich-Loeffler-Institut, Institute of Farm Animal Genetics, Department of Biotechnology, Mariensee 31535, Germany.
National Research Centre on Equines · INCentral Institute for Research on Buffaloes · INFriedrich-Loeffler-Institut · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Induced pluripotent stem (iPS) cells present a seminal discovery in cell biology and promise to support innovative treatments of so far incurable diseases. To translate iPS technology into clinical trials, the safety and stability of these reprogrammed cells needs to be shown. In recent years, different non-viral transposon systems have been developed for the induction of cellular pluripotency, and for the directed differentiation into desired cell types. In this review, we summarize the current state of the art of different transposon systems in iPS-based cell therapies.

Indexed as

Cell-based therapyCellular reprogrammingClinical applicationsGenetic correctionInduced pluripotent stem cellsTransposons

Identifiers

PMID32843912
PMCPMC7415244
OpenAlexW3044728415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.